Pandox AB (PNDX.B) AI Stock Analysis

• Market Cap: kr36.86B
• Dividend Yield: 2.24%
• Average Volume (3M): 171.66K
• Price to Earnings (P/E): 18.2
• Beta (1Y): 0.75
• Revenue Growth: 2.86%
• EPS Growth: N/A
• Country: SE
• Employees: 1,505
• Sector: Real Estate
• Sector Strength: 53
• Industry: Travel Lodging
• EPS (TTM): 3.17
• Shares Outstanding: 119,603,000
• 10 Day Avg. Volume: 206,458
• 30 Day Avg. Volume: 171,662
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 65 Neutral
• Price Target: kr190.00 ▲(2.37% Upside)

Pandox AB's stock score is driven by strong revenue growth and operational efficiency, as well as bullish technical indicators. However, concerns about declining net profit margins, return on equity, and negative free cash flow weigh on the score. The valuation is reasonable but not compelling, given the financial challenges.

Pandox AB Business Overview & Revenue Model

Company Description

Pandox AB (publ) owns, operates, and leases hotel properties. The company operates through Property Management and Operator Activities segments. As of March 11, 2022, it operated 157 hotels with approximately 35,500 hotel rooms in 15 countries. The company was founded in 1932 and is based in Stockholm, Sweden.

How the Company Makes Money

Pandox generates revenue through multiple streams, primarily from the leasing and management of hotel properties. The company earns income from long-term leases with hotel operators, where it collects fixed and variable rent based on the performance of the hotel. Additionally, Pandox manages hotels on behalf of third parties, receiving management fees tied to revenue performance. Key partnerships with established hotel brands and operators enhance its revenue potential, as the company can leverage these relationships to improve occupancy rates and profitability. Furthermore, Pandox's strategy of renovating and upgrading its properties adds value, which can lead to increased rental income and asset appreciation, contributing significantly to its overall earnings.

Pandox AB Financial Statement Overview

Summary

Pandox AB shows strong revenue growth and maintains healthy margins, which are positive indicators of operational efficiency. However, the decline in net profit margin and return on equity, coupled with negative free cash flow, suggest areas of concern that could impact financial stability. The company's leverage is moderate, but careful management is needed to mitigate potential risks associated with debt levels.

Income Statement

Pandox AB has demonstrated strong revenue growth, particularly in the TTM period with a 51.7% increase. The company maintains robust gross and EBIT margins at 54.38% and 47.86% respectively, indicating efficient cost management and operational effectiveness. However, the net profit margin has decreased from 23.67% in 2024 to 18.97% in the TTM period, suggesting increased expenses or other financial pressures impacting net income.

Balance Sheet

The company's debt-to-equity ratio stands at 1.26, reflecting a moderate level of leverage, which is typical for the industry but could pose risks if interest rates rise. Return on equity has decreased to 4.18% in the TTM period, indicating reduced profitability from shareholders' equity. The equity ratio is stable, suggesting a balanced asset structure.

Cash Flow

Pandox AB's cash flow performance is mixed. The operating cash flow to net income ratio is 0.47, indicating that operating cash flows cover less than half of net income, which may affect liquidity. The free cash flow is negative in the TTM period, highlighting potential challenges in generating cash after capital expenditures. However, there is a positive trend in free cash flow growth, suggesting potential future improvements.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.19B	7.14B	6.88B	5.65B	3.27B	3.18B
Gross Profit	3.91B	3.85B	3.62B	3.10B	1.73B	1.61B
EBITDA	3.75B	3.96B	1.87B	4.36B	1.46B	-202.00M
Net Income	1.36B	1.69B	-585.00M	4.22B	610.00M	-1.41B
Balance Sheet
Total Assets	81.60B	80.69B	73.21B	75.22B	66.80B	64.81B
Cash, Cash Equivalents and Short-Term Investments	2.22B	1.29B	769.00M	1.63B	1.59B	2.62B
Total Debt	40.88B	38.70B	35.63B	37.09B	35.66B	34.38B
Total Liabilities	48.88B	46.99B	43.48B	44.28B	41.38B	40.73B
Stockholders Equity	32.54B	33.53B	29.57B	30.73B	25.21B	23.88B
Cash Flow
Free Cash Flow	-2.27B	802.00M	1.27B	1.04B	-479.00M	-644.00M
Operating Cash Flow	1.92B	1.83B	2.19B	2.38B	430.00M	460.00M
Investing Cash Flow	-6.49B	-4.12B	-1.48B	-1.64B	-1.52B	-1.60B
Financing Cash Flow	5.90B	2.70B	-1.70B	-806.00M	93.00M	3.07B

Pandox AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 185.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PNDX.B, the sentiment is Positive. The current price of 185.6 is below the 20-day moving average (MA) of 186.01, above the 50-day MA of 178.51, and above the 200-day MA of 173.93, indicating a bullish trend. The MACD of 4.39 indicates Negative momentum. The RSI at 57.84 is Neutral, neither overbought nor oversold. The STOCH value of 64.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:PNDX.B.

Pandox AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WIHL	―	kr28.38B	12.72	9.74%	3.47%	5.18%	349.60%
ATRLJ.B	―	kr21.90B	20.10	3.82%	2.10%	-1.74%	1579.70%
Sector *	―	$2.17B	12.19	3.79%	4.94%	3.15%	1.96%
PNDX.B	―	kr36.86B	18.17	6.23%	2.24%	2.86%	―
SHOT	―	€18.20B	24.94	21.87%	4.11%	1.45%	34.85%
HUFV.A	―	kr24.54B	25.98	3.50%	2.22%	6.42%	―
FABG	―	kr26.61B	93.43	0.76%	2.31%	-3.46%	―

Pandox AB Corporate Events

Pandox AB Reports Strong Q3 2025 Results and Strategic Acquisition

Pandox AB reported a solid financial performance for the third quarter of 2025, with a notable increase in revenues and net operating income across its leasing and own operations segments. The company announced a significant acquisition of Dalata Hotel Group plc, expected to enhance its portfolio with 31 new investment properties, potentially increasing its market value and profitability. This strategic move is anticipated to strengthen Pandox’s position in the hotel property market, particularly in the UK and Ireland, and is expected to yield substantial rental income, aligning with the company’s existing agreements.

The most recent analyst rating on ($SE:PNDX.B) stock is a Hold with a SEK190.00 price target. To see the full list of analyst forecasts on Pandox AB stock, see the SE:PNDX.B Stock Forecast page.

Pandox AB to Release Interim Report and Host Market Data Presentation

Pandox AB announced the release of its interim report for January to September 2025, scheduled for October 23, 2025. The report’s presentation will be followed by a webcasted conference featuring market data presentations on the international and Nordic hotel markets by independent experts. This event highlights Pandox’s commitment to transparency and provides stakeholders with valuable insights into market trends, potentially impacting the company’s strategic decisions and industry positioning.

The most recent analyst rating on ($SE:PNDX.B) stock is a Hold with a SEK190.00 price target. To see the full list of analyst forecasts on Pandox AB stock, see the SE:PNDX.B Stock Forecast page.

Pandox AB Advances in Dalata Acquisition with EU Clearance

Pandox AB has received EU Commission clearance for its acquisition of Dalata Hotel Group plc, marking a significant milestone towards completing the transaction. The acquisition, facilitated through a court-sanctioned scheme, is expected to close by early November 2025, pending final court approval, which could enhance Pandox’s market position in the hotel industry.

Pandox Completes Acquisition of Elite Hotel Frost Kiruna

Pandox AB has finalized the acquisition of Elite Hotel Frost Kiruna, integrating it into their business segment Leases as of September 30, 2025, with a transaction value of approximately MSEK 347. This acquisition strengthens Pandox’s position in the hotel property market, potentially enhancing their portfolio value and offering more opportunities for growth in Northern Europe.

The most recent analyst rating on ($SE:PNDX.B) stock is a Hold with a SEK190.00 price target. To see the full list of analyst forecasts on Pandox AB stock, see the SE:PNDX.B Stock Forecast page.

Pandox AB Moves Closer to Acquiring Dalata Hotel Group

Pandox AB announced that Dalata Hotel Group plc’s shareholders have approved all resolutions related to Pandox’s acquisition of Dalata’s entire share capital. This approval marks a significant step towards completing the acquisition, which is expected to be finalized by the end of November 2025, pending court sanction and other conditions. The acquisition is set to enhance Pandox’s position in the hotel industry, potentially impacting stakeholders by expanding its portfolio and market influence.

Pandox AB Forms Nomination Committee for 2026 AGM

Pandox AB has announced the formation of its nomination committee for the 2026 annual general meeting, consisting of representatives from its largest shareholders and the chairman of the board. This committee is responsible for proposing the composition of the board, with the proposals to be presented in the notice for the AGM scheduled for April 2026. This move is in line with the principles adopted at the 2025 AGM and reflects Pandox’s commitment to structured governance and stakeholder engagement.

The most recent analyst rating on ($SE:PNDX.B) stock is a Hold with a SEK180.00 price target. To see the full list of analyst forecasts on Pandox AB stock, see the SE:PNDX.B Stock Forecast page.